Medical Program: semaglutide in obesity-related HFpEF + T2D

Media formats available:

Ready to Claim Your Credits?

You have attempts to pass this post-test. Take your time and review carefully before submitting.

Good luck!

Effects of aldose reductase inhibitor on exercise capacity in diabetic cardiomyopathy
Effects of aldose reductase inhibitor on exercise capacity in diabetic cardiomyopathy
ACC.24
Effects of aldose reductase inhibitor on exercise capacity in diabetic cardiomyopathy
- James Januzzi, MD
Targeting cardiac energetics with cardiac mitotrope in nonobstructive HCM
Targeting cardiac energetics with cardiac mitotrope in nonobstructive HCM
ACC.24
Targeting cardiac energetics with cardiac mitotrope in nonobstructive HCM
- Martin Maron, MD
Long-term improvements in daily steps with gamification and financial incentives in patients at risk for CV events
Long-term improvements in daily steps with gamification and financial incentives in patients at risk for CV events
ACC.24
Long-term improvements in daily steps with gamification and financial incentives in patients at risk for CV events
- Alexander Fanaroff, MD
Angiotensinogen RNAi therapeutic lowers blood pressure in combination with standard antihypertensive
Angiotensinogen RNAi therapeutic lowers blood pressure in combination with standard antihypertensive
ACC.24
Angiotensinogen RNAi therapeutic lowers blood pressure in combination with standard antihypertensive
- Akshay S. Desai, MD

Beneficial effects of GLP-1RA in patients with obesity-related HFpEF and T2D